MedCity News

医药城新闻

INVEST 2025

投资2025

, scheduled for May 20 and 21 at Chicago’s Willis

，定于5月20日和21日在芝加哥的威利斯

Tower, is a boutique healthcare investment conference where healthcare startups, investors, and healthcare stakeholders convene. The startups pitch contest Pitch Perfect is at the center of the conference, with entrepreneurs presenting their approaches to addressing unmet needs or inadequately met needs to a panel of investor judges.

Tower是一家精品医疗保健投资会议，医疗保健初创公司、投资者和医疗保健相关方齐聚一堂。会议的核心是初创公司进行的名为“Pitch Perfect”的路演比赛，企业家们向一组投资评委展示他们解决未满足或未充分满足需求的方法。

One of the judges is Charity Tarn, an investor with .

其中一位评委是查丽蒂·塔恩，她是一名投资者。

Arboretum Ventures

阿博雷特姆风险投资公司

.

。

Tarn is one of three judges for the devices and diagnostics Pitch Perfect track, which focuses on chronic disease management. She will be joined by Jenni Le, an investor and principal with

塔恩是设备和诊断Pitch Perfect赛道的三位评委之一，该赛道专注于慢性病管理。她将与投资者兼负责人詹妮·乐一同参与。

Venture Investors Health Fund

风险投资健康基金

, and Ashish Atreja, a professor of IT Business Operations and Gastroenterology at UC Davis Health.

，以及加州大学戴维斯健康分校IT商业运营和胃肠病学教授阿希什·阿特雷贾。

In response to emailed questions she shared her perspective as a healthcare investor and some of the challenges startups face in the current investment landscape.

她通过电子邮件回复了提问，分享了她作为医疗保健领域投资者的看法，以及初创公司在当前投资环境中面临的一些挑战。

To review the agenda for INVEST,

要查看INVEST的议程，

click here

点击这里

. You can also

. 你也可以

register here

注册这里

.

。

What subsector of health tech, medtech or biotech is your firm allocating more investment in 2025 and what’s an area you are moving away from? Why?

您的公司在2025年将更多投资于健康科技、医疗科技还是生物技术的哪个子领域？您正在退出的领域是哪个？为什么？

The four pillars of our investment thesis include medtech, healthtech, life science tools and diagnostics, and pharma adjacent technologies. Our current portfolio weighs more towards medical devices. We aren’t moving away from our core thesis, but we are taking a fresh look at tech-enabled services and healthcare IT, spaces that we have historically found success in, but have been such dynamic ecosystems.

我们投资理论的四大支柱包括医疗技术、健康科技、生命科学工具与诊断，以及制药相关技术。我们当前的投资组合更倾向于医疗器械领域。我们并未偏离核心投资理论，但正在重新审视技术赋能的服务和医疗信息技术领域，这些领域我们过去曾取得成功，但其生态系统一直充满活力且变化多端。

I’m excited about the potential opportunities that will emerge in the next couple of years..

我对未来几年将出现的潜在机会感到兴奋。

Have you seen any shifts in the way startups seek investment in the past couple of years?

过去几年，您是否看到过初创公司在寻求投资方式上的任何变化？

I think the fundraising environment has been very tough, and financing risk has increased. I think startups have adapted by becoming increasingly capital efficient and are giving extra scrutiny in defining value-driving milestones in anticipation of future funding needs.

我认为融资环境非常艰难，融资风险也增加了。 我认为初创公司已经通过提高资本效率来适应这种情况，并且在预估未来资金需求时，对定义价值驱动的里程碑给予了额外的审视。

Have you seen a shift in healthcare or biopharma strategic investor priorities in recent years?

近年来，您是否看到医疗保健或生物制药战略投资者的优先事项发生了变化？

I think uncertainties in the macro environment may drive priorities to more de-risked investments with more predictable business models, and investments that are more immediately accretive.

我认为宏观环境的不确定性可能会促使投资者优先考虑风险较低、商业模式更具可预测性的投资，以及能够更快产生收益的投资。

What is an example of a portfolio company’s work you are particularly proud of?

您特别引以为豪的投资组合公司的工作案例是什么？

I am very proud of the team at

我为团队感到非常自豪

SonarMD

声纳医疗

and what they’ve achieved. Last year was an important year, and the team worked through some tough commercial headwinds and strategic questions that put the company on track to further growth and helping more GI patients manage their symptoms and care. The value-based care world is not easy to navigate!.

以及他们所取得的成就。去年是重要的一年，团队克服了一些严峻的商业逆风和战略问题，使公司走上了进一步增长的轨道，帮助更多的胃肠病患者管理他们的症状和护理。基于价值的医疗世界并不容易驾驭！

Photo:

照片：

DNY59, Getty Images

DNY59，Getty Images